Clinical Trial: Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

U.S., April 5 -- ClinicalTrials.gov registry received information related to the study (NCT06911320) titled 'Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function' on March 24.

Brief Summary: To Assess the Effect of Severe Hepatic or Renal Impairment on the Pharmacokinetics of Bemnifosbuvir/Ruzasvir After a Single Dose

Study Start Date: April, 2025

Study Type: INTERVENTIONAL

Condition: Healthy Volunteer Study Hepatic Impairment Renal Impairment

Intervention: DRUG: Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination

A single dose of BEM/RZR will be administered

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Atea Pharmaceuticals, Inc.

Published...